tetano
Editor, Senior Moderator
Rev Invest Clin
. 2020;72(3):159-164.
doi: 10.24875/RIC.20000237.
INFUSION OF CONVALESCENT PLASMA IS ASSOCIATED WITH CLINICAL IMPROVEMENT IN CRITICALLY ILL PATIENTS WITH COVID-19: A PILOT STUDY
Juan C Olivares-Gazca[SUP] 1 2 [/SUP], Jose M Priesca-Mar?n[SUP] 1 [/SUP], Mart?n Ojeda-Laguna[SUP] 1 [/SUP], Javier Garces-Eisele[SUP] 2 3 [/SUP], Silvia Soto-Olvera[SUP] 3 [/SUP], Abraham Palacios-Alonso[SUP] 4 [/SUP], Judith Izquierdo-Vega[SUP] 4 [/SUP], R?mulo Chacon-Cano[SUP] 5 [/SUP], Daniel Arizpe-Bravo[SUP] 5 [/SUP], Miguel A L?pez-Trujillo[SUP] 3 [/SUP], Yahveth Cantero-Fortiz[SUP] 1 6 [/SUP], Danitza Fernandez-Lara[SUP] 1 2 [/SUP], Guillermo J Ruiz-Delgado[SUP] 1 3 [/SUP], Guillermo J Ruiz-Arg?elles[SUP] 1 5 [/SUP]
Affiliations
Abstract
Background: The ideal treatment of coronavirus disease (COVID)-19 has yet to be defined, but convalescent plasma (CoPla) has been successfully employed.
Objective: The objective of the study was to study the safety and outcomes of the administration of CoPla to individuals with severe COVID-19 in an academic medical center.
Methods: Ten patients were prospectively treated with plasma from COVID-19 convalescent donors.
Results: Over 8 days, the sequential organ failure assessment score dropped significantly in all patients, from 3 to 1.5 (p = 0.014); the Kirby index (PaO[SUB]2[/SUB]/FiO[SUB]2[/SUB]) score increased from 124 to 255, (p < 0.0001), body temperature decreased significantly from 38.1 to 36.9?C (p = 0.0058), and ferritin levels also dropped significantly from 1736.6 to 1061.8 ng/ml (p = 0.0001). Chest X-rays improved in 7/10 cases and in 6/10, computerized tomography scans also revealed improvement of the lung injury. Decreases in C-reactive protein and D-dimer levels were also observed. Three of five patients on mechanical ventilation support could be extubated, nine were transferred to conventional hospital floors, and six were sent home; two patients died. The administration of CoPla had no side effects and the 24-day overall survival was 77%.
Conclusions: Although other treatments were also administered to the patients and as a result data are difficult to interpret, it seems that the addition of CoPla improved pulmonary function.
Keywords: Convalescent plasma; Coronavirus disease-19; Severe coronavirus disease-19.
. 2020;72(3):159-164.
doi: 10.24875/RIC.20000237.
INFUSION OF CONVALESCENT PLASMA IS ASSOCIATED WITH CLINICAL IMPROVEMENT IN CRITICALLY ILL PATIENTS WITH COVID-19: A PILOT STUDY
Juan C Olivares-Gazca[SUP] 1 2 [/SUP], Jose M Priesca-Mar?n[SUP] 1 [/SUP], Mart?n Ojeda-Laguna[SUP] 1 [/SUP], Javier Garces-Eisele[SUP] 2 3 [/SUP], Silvia Soto-Olvera[SUP] 3 [/SUP], Abraham Palacios-Alonso[SUP] 4 [/SUP], Judith Izquierdo-Vega[SUP] 4 [/SUP], R?mulo Chacon-Cano[SUP] 5 [/SUP], Daniel Arizpe-Bravo[SUP] 5 [/SUP], Miguel A L?pez-Trujillo[SUP] 3 [/SUP], Yahveth Cantero-Fortiz[SUP] 1 6 [/SUP], Danitza Fernandez-Lara[SUP] 1 2 [/SUP], Guillermo J Ruiz-Delgado[SUP] 1 3 [/SUP], Guillermo J Ruiz-Arg?elles[SUP] 1 5 [/SUP]
Affiliations
- PMID: 32584322
- DOI: 10.24875/RIC.20000237
Abstract
Background: The ideal treatment of coronavirus disease (COVID)-19 has yet to be defined, but convalescent plasma (CoPla) has been successfully employed.
Objective: The objective of the study was to study the safety and outcomes of the administration of CoPla to individuals with severe COVID-19 in an academic medical center.
Methods: Ten patients were prospectively treated with plasma from COVID-19 convalescent donors.
Results: Over 8 days, the sequential organ failure assessment score dropped significantly in all patients, from 3 to 1.5 (p = 0.014); the Kirby index (PaO[SUB]2[/SUB]/FiO[SUB]2[/SUB]) score increased from 124 to 255, (p < 0.0001), body temperature decreased significantly from 38.1 to 36.9?C (p = 0.0058), and ferritin levels also dropped significantly from 1736.6 to 1061.8 ng/ml (p = 0.0001). Chest X-rays improved in 7/10 cases and in 6/10, computerized tomography scans also revealed improvement of the lung injury. Decreases in C-reactive protein and D-dimer levels were also observed. Three of five patients on mechanical ventilation support could be extubated, nine were transferred to conventional hospital floors, and six were sent home; two patients died. The administration of CoPla had no side effects and the 24-day overall survival was 77%.
Conclusions: Although other treatments were also administered to the patients and as a result data are difficult to interpret, it seems that the addition of CoPla improved pulmonary function.
Keywords: Convalescent plasma; Coronavirus disease-19; Severe coronavirus disease-19.